Geiger R
Arzneimittelforschung. 1984;34(10B):1386-91.
The enzyme renin splits a single peptide bond in the plasma glycoprotein angiotensinogen liberating the biologically inactive decapeptide angiotensin I (ANG I). A second enzyme, angiotensin converting enzyme (CE), releases the strong vasoconstricting octapeptide ANG II via degradation of a C-terminal dipeptide. The effect of this compound on blood pressure can be attenuated by interference with the enzyme-controlled peptide cascade of the renin-angiotensin system (RAS). This is accomplished by inhibition of renin and CE, respectively. Orally active CE inhibitors are valuable drugs in the treatment of renal and essential hypertension and of heart failure. Strong inhibitors of renin have also been synthesized, however, peptide moieties which have still to be present in these compounds impede oral absorption. Finally, antagonistic analogues of ANG II are able to block its effect on the receptor level. Their application is limited by the still existing partial agonistic activity.
肾素酶可将血浆糖蛋白血管紧张素原中的一个肽键切开,释放出无生物活性的十肽血管紧张素I(ANG I)。另一种酶,即血管紧张素转换酶(CE),通过降解C末端二肽释放出强烈的血管收缩八肽ANG II。该化合物对血压的影响可通过干扰肾素-血管紧张素系统(RAS)的酶控肽级联反应来减弱。这分别通过抑制肾素和CE来实现。口服活性CE抑制剂是治疗肾性高血压、原发性高血压和心力衰竭的重要药物。也已合成了肾素的强效抑制剂,然而,这些化合物中仍需存在的肽部分会阻碍口服吸收。最后,ANG II的拮抗类似物能够在受体水平阻断其作用。它们的应用受到仍然存在的部分激动活性的限制。